Advertisement

Somatic tumor testing implications for Lynch syndrome germline genetic testing

      Abstract

      Clinicians involved in cancer treatment often utilize somatic tumor sequencing to help tailor chemotherapy and immunotherapy. However, somatic tumor sequencing can also identify patients at risk for germline pathogenic variants causing cancer predisposition syndromes like Lynch syndrome. The extent to which clinicians realize this implication of tumor sequencing is currently unclear. We performed a retrospective chart review of Stanford Health Care patients who had somatic variant(s) in the Lynch syndrome genes or microsatellite instability identified on tumor sequencing to determine the proportion of patients who were referred to genetics. Among 6,556 patients who had tumor testing, 90 (1.37%) had findings compatible with Lynch syndrome. Of the 62 patients who had not already seen genetics, 47/62 (75.8%) were not referred to genetics for germline testing. Additionally, 26/47 (55.3%) of these individuals had a tumor type within the Lynch syndrome spectrum. Of the 10 patients who did elect germline testing after tumor sequencing, 3/10 were positive for Lynch syndrome. Our study highlights the need for specific guidelines to inform clinician referral practices on germline follow-up of somatic tumor testing and demonstrates the importance of continued research on the relationship between somatic tumor variants and germline variants to inform such guidelines.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Schwartzberg L
        • Kim ES
        • Liu D
        • Schrag D.
        Precision oncology: who, how, what, when, and when not?.
        Am Soc Clin Oncol Educ B. 2017; : 160-169https://doi.org/10.1200/edbk_174176
        • Brittain HK
        • Scott R
        • Thomas E.
        The rise of the genome and personalised medicine.
        Clin Med J R Coll Physicians London. 2017; 17: 545-551https://doi.org/10.7861/clinmedicine.17-6-545
        • Zehir A
        • Benayed R
        • Shah RH
        • Syed A
        • Middha S
        • Kim HR
        • et al.
        Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
        Nat Med. 2017; 23: 703-713https://doi.org/10.1038/nm.4333
        • Alldredge J
        • Randall L
        Germline and Somatic Tumor Testing in Gynecologic Cancer Care.
        Obstet Gynecol Clin North Am. 2019; 46: 37-53https://doi.org/10.1016/j.ogc.2018.09.003
        • Bruinooge SS
        • Sherwood S
        • Grubbs S
        • Schilsky RL.
        Determining if a somatic tumor mutation is targetable and options for accessing targeted therapies.
        J Oncol Pract. 2019; 15: 575-583https://doi.org/10.1200/jop.19.00262
        • Tran E
        • Robbins PF
        • Rosenberg SA.
        Final common pathway’ of human cancer immunotherapy: Targeting random somatic mutations.
        Nat Immunol. 2017; 18: 255-262https://doi.org/10.1038/ni.3682
        • Cimadamore A
        • Lopez-Beltran A
        • Massari F
        • Santoni M
        • Mazzucchelli R
        • Scarpelli M
        • et al.
        Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
        Futur Oncol. 2020; 16: 75-80https://doi.org/10.2217/fon-2019-0745
        • Li MM
        • Datto M
        • Duncavage EJ
        • Kulkarni S
        • Lindeman NI
        • Roy S
        • et al.
        Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists.
        J Mol Diagn. 2017; 19: 4-23https://doi.org/10.1016/j.jmoldx.2016.10.002
        • Raymond VM
        • Gray SW
        • Roychowdhury S
        • Joffe S
        • Chinnaiyan AM
        • Parsons DW
        • et al.
        Germline findings in tumor-only sequencing: points to consider for clinicians and laboratories.
        J Natl Cancer Inst. 2016; 108: djv351https://doi.org/10.1093/jnci/djv351
        • Mandelker D
        • Zhang L.
        The emerging significance of secondary germline testing in cancer genomics.
        J Pathol. 2018; 244: 610-615https://doi.org/10.1002/path.5031
        • Vlessis K
        • Purington N
        • Chun N
        • Haraldsdottir S
        • Ford JM.
        Germline Testing for Patients with BRCA1/2 Mutations on Somatic Tumor Testing.
        JNCI Cancer Spectr. 2019; 4: 4pkz095https://doi.org/10.1093/jncics/pkz095
        • Schrader KA
        • Cheng DT
        • Joseph V
        • Prasad M
        • Walsh M
        • Zehir A
        • et al.
        Germline variants in targeted tumor sequencing using matched normal DNA.
        JAMA Oncol. 2016; 2: 104https://doi.org/10.1001/jamaoncol.2015.5208
        • National Comprehensive Cancer Network [Internet]
        NCCN clinical practice guidelines in oncology genetic/familial high-risk assessment: colorectal.
        2021 ([cited 2021 Aug 30]Available from)
        • Win AK
        • Jenkins MA
        • Dowty JG
        • Antoniou AC
        • Lee A
        • Giles GG
        • et al.
        Prevalence and penetrance of major genes and polygenes for colorectal cancer.
        Cancer Epidemiol Biomarkers Prev. 2017; 26: 404-412https://doi.org/10.1158/1055-9965.EPI-16-0693
        • Bruegl AS
        • Kernberg A
        • Broaddus RR.
        Importance of PCR-based tumor testing in the evaluation of lynch syndrome-associated endometrial cancer.
        Adv Anat Pathol. 2017; 24: 372-378https://doi.org/10.1097/PAP.0000000000000169
        • Hampel H
        • Bennett RL
        • Buchanan A
        • Pearlman R
        • Wiesner GL.
        A practice guideline from the American college of medical genetics and genomics and the national society of genetic counselors: referral indications for cancer predisposition assessment.
        Genet Med. 2015; 17: 70-87https://doi.org/10.1038/gim.2014.147
        • Adar T
        • Rodgers LH
        • Shannon KM
        • Yoshida M
        • Ma T
        • Mattia A
        • et al.
        Universal screening of both endometrial and colon cancers increases the detection of Lynch syndrome.
        Cancer. 2018; 124: 3145-3153https://doi.org/10.1002/cncr.31534
        • Dillon JL
        • Gonzalez JL
        • DeMars L
        • Bloch KJ
        • Tafe LJ.
        Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
        Hum Pathol. 2017; 70: 121-128https://doi.org/10.1016/j.humpath.2017.10.022
        • Watkins JC
        • Yang EJ
        • Muto MG
        • Feltmate CM
        • Berkowitz RS
        • Horowitz NS
        • et al.
        Universal screening for mismatch-repair deficiency in endometrial cancers to identify patients with lynch syndrome and lynch-like syndrome.
        Int J Gynecol Pathol. 2017; 36: 115-127https://doi.org/10.1097/PGP.0000000000000312
        • Ladabaum U
        • Wang G
        • Terdiman J
        • Blanco A
        • Kuppermann M
        • Boland CR
        • et al.
        Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.
        Ann Intern Med. 2011; 155 (10.7326/0003-4819-155-2-201107190-00002.): 69-79
        • Le DT
        • Uram JN
        • Wang H
        • Bartlett BR
        • Kemberling H
        • Eyring AD
        • et al.
        PD-1 blockade in tumors with mismatch-repair deficiency.
        N Engl J Med. 2015; 372: 2509-2520https://doi.org/10.1056/NEJMoa1500596
        • Core Team R
        R: A language and environment for statistical computing.
        R Foundation for Statistical Computing, Vienna, Austria2020 (URL)
        • Latham A
        • Srinivasan P
        • Kemel Y
        • Shia J
        • Bandlamudi C
        • Mandelker D
        • et al.
        Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer.
        J Clin Oncol. 2019; 37: 286-295https://doi.org/10.1200/JCO.18.00283
        • Pino MS
        • Mino-Kenudson M
        • Wildemore BM
        • Ganguly A
        • Batten J
        • Sperduti I
        • et al.
        Deficient DNA mismatch repair is common in Lynch syndrome-associated colorectal adenomas.
        J Mol Diagn. 2009; 11: 238-247https://doi.org/10.2353/jmoldx.2009.080142